GSK Files Promacta NDA For Short-Term Treatment Of ITP
If approved, drug will be first oral platelet growth factor for idiopathic thrombocytopenic purpura.
If approved, drug will be first oral platelet growth factor for idiopathic thrombocytopenic purpura.